Skarping, I.
Larsson, M.
Förnvik, D.
Funding for this research was provided by:
Swedish Breast Cancer Group
Allmänna Sjukhusets i Malmö Stiftelse för Bekämpande av Cancer
the Governmental Funding of Clinical Research within the National Health Services
Lund University
Article History
Received: 31 May 2021
Revised: 28 August 2021
Accepted: 2 September 2021
First Online: 15 October 2021
Change Date: 22 February 2022
Change Type: Update
Change Details: In this article the following funding information was added: Open access funding provided by Lund University.
Declarations
:
: The scientific guarantor of this publication is associated professor Daniel Förnvik, Lund University.
: The authors declare they have no competing interests.
: No complex statistical methods were necessary for this paper.
: The general informed consents provided for the two cohorts at inclusion comprises the current study. More specifically, a general written consent, meeting the content of this current study, was obtained from the prospectively included patients at the time of inclusion. In accordance with the decision from the ethics committee regarding the retrospectively included patients, an “opt-out”-methodology was used and subsequently no written consent was obtained for these patients.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Regional Ethics Committee in Lund, Sweden (committee’s reference number: 2014/13, 2014/521, and 2016/521).
: Some study subjects or cohorts have been previously reported in:Published:- Skarping I, Fornvik D, Heide-Jorgensen U, et al. Mammographic density changes during neoadjuvant breast cancer treatment: NeoDense, a prospective study in Sweden. Breast. 2020 Oct;53:33–41. (Overlap: This study is based on the prospective cohort included in the current study. In this study, we investigated mammographic density (using VolparaTM) and its association with pCR).- Skarping I, Fornvik D, Sartor H, et al. Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer. BMC Cancer. 2019 Dec 30;19(1):1272. (Overlap: This study is based on the retrospective cohort included in the current study. In this study, we investigated mammogrpohic density (using Volpara <sup>TM</sup>) and its association with pCR)..- Skarping I, Fornvik D, Heide-Jorgensen U, et al. Mammographic density as an image-based biomarker of therapy response in neoadjuvant-treated breast cancer patients. Cancer Causes Control. 2021 Mar;32(3):251–260. (Overlap: This study is based on the retrospective and prospective cohort included in the current study. In this study, we investigated mammographic density (BI-RADS) and its association with pCR).- Skarping I, Fornvik D, Heide-Jorgensen U, et al. Neoadjuvant breast cancer treatment response; tumour size evaluation through different conventional imaging modalities in the NeoDense study. Acta Oncol. 2020 Dec;59(12):1528–1537. (Overlap: This study is based on the prospective cohort included in the current study. In this study, we investigated different aspects of conventional imaging (mammography, ultrasound and tomosynthesis) during neoadjuvant chemotherapy for breast cancer).Submitted: Skarping I, Blaabjerg Pedersen S, Förnvik D, Zackrisson S, Borgquist S. The association between body mass index and pathological complete response in neoadjuvant-treated breast cancer patients. (Overlap: This study is based on the retrospective and prospective cohort included in the current study. In this study, we investigated body mass index and its association with pCR)
: • prospective• diagnostic or prognostic study, observational cohort study• performed at one institution